Citadel Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-86,464
| Closed | -$3.32M | – | 15544 |
|
|
2023
Q2 | $3.32M | Sell |
86,464
-25,717
| -23% | -$660K | ﹤0.01% | 4287 |
|
|
2023
Q1 | $2.6M | Sell |
112,181
-398,986
| -78% | -$9.51M | ﹤0.01% | 4886 |
|
|
2022
Q4 | $13.4M | Buy |
511,167
+290,148
| +131% | +$6.43M | ﹤0.01% | 2432 |
|
|
2022
Q3 | $4.34M | Buy |
221,019
+104,668
| +90% | +$2.1M | ﹤0.01% | 4109 |
|
|
2022
Q2 | $2.04M | Buy |
116,351
+88,902
| +324% | +$1.4M | ﹤0.01% | 5510 |
|
|
2022
Q1 | $450K | Buy |
27,449
+15,021
| +121% | +$204K | ﹤0.01% | 9651 |
|
|
2021
Q4 | $203K | Sell |
12,428
-139,755
| -92% | -$1.99M | ﹤0.01% | 11825 |
|
|
2021
Q3 | $1.94M | Sell |
152,183
-99,439
| -40% | -$1.31M | ﹤0.01% | 6433 |
|
|
2021
Q2 | $3.55M | Sell |
251,622
-253,134
| -50% | -$4.05M | ﹤0.01% | 5215 |
|
|
2021
Q1 | $7.8M | Sell |
504,756
-42
| -0% | -$685 | ﹤0.01% | 3385 |
|
|
2020
Q4 | $8.01M | Buy |
504,798
+501,844
| +16,989% | +$7.57M | ﹤0.01% | 2939 |
|
|
2020
Q3 | $36K | Buy |
+2,954
| New | +$39.6K | ﹤0.01% | 9713 |
|
|
2020
Q2 | – | Sell |
-11,631
| Closed | -$159K | – | 10704 |
|
|
2020
Q1 | $159K | Buy |
11,631
+343
| +3% | +$4.06K | ﹤0.01% | 8235 |
|
|
2019
Q4 | $67K | Buy |
+11,288
| New | +$61.3K | ﹤0.01% | 8679 |
|
|
2019
Q3 | – | Sell |
-12,349
| Closed | -$95K | – | 9926 |
|
|
2019
Q2 | $95K | Sell |
12,349
-147,443
| -92% | -$2.25M | ﹤0.01% | 8547 |
|
|
2019
Q1 | $3.18M | Sell |
159,792
-336,353
| -68% | -$5.87M | ﹤0.01% | 3660 |
|
|
2018
Q4 | $6.55M | Buy |
496,145
+142,289
| +40% | +$2.84M | ﹤0.01% | 2425 |
|
|
2018
Q3 | $13M | Buy |
353,856
+35,690
| +11% | +$1.15M | 0.01% | 1810 |
|
|
2018
Q2 | $11.1M | Buy |
318,166
+285,909
| +886% | +$11M | 0.01% | 1823 |
|
|
2018
Q1 | $1.5M | Sell |
32,257
-2,656
| -8% | -$97.2K | ﹤0.01% | 4179 |
|
|
2017
Q4 | $1.31M | Buy |
+34,913
| New | +$1.52M | ﹤0.01% | 4260 |
|
|
2017
Q2 | – | Sell |
-11,784
| Closed | -$633K | – | 8240 |
|
|
2017
Q1 | $633K | Buy |
+11,784
| New | +$666K | ﹤0.01% | 4667 |
|
|
2016
Q2 | – | Sell |
-12,652
| Closed | -$810K | – | 7566 |
|
|
2016
Q1 | $810K | Buy |
+12,652
| New | +$1.02M | ﹤0.01% | 3730 |
|
|
2015
Q3 | – | Sell |
-6,541
| Closed | -$992K | – | 9331 |
|
|
2015
Q2 | $992K | Buy |
+6,541
| New | +$1.08M | ﹤0.01% | 3965 |
|
Citadel Advisors's KDNY Position: Q3 2023 in Review
Citadel Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 86,464 shares — an estimated $3.32M sold.
Citadel Advisors first reported a position in KDNY in Q2 2015 and held it in 24 quarters. The position peaked at $13.4M in Q4 2022. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Citadel Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Citadel Advisors sold 86,464 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $3.32M.
- Citadel Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 24 quarters.
- Citadel Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $13.4M in Q4 2022.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.